There's been another twist to the tale of Advanz Pharma's efforts to keep its primary biliary cholangitis (PBC) therapy Ocaliva on the market in the EU.

The EU application included data showing Gilenya 0.5 mg reduced relapses by 52% (P<0.001) at one year compared with interferon beta-1a IM (Avonex®), one of the most commonly prescribed treatments ...

As expected, the European Union socked it to pharma in a new industry-sector report, saying that drugmakers' business strategies have added billions to healthcare costs. By delaying or blocking the ...

EU releases proposed pharma overhaul, cutting period of market exclusivity. By Andrew Joseph April 26, 2023. Reprints. Sean Gallup/Getty Images.

EU, UK strike ‘historic’ Gibraltar deal to cut border checks, boost trade 11-06-2025 Czech innovative drug makers welcome Council pharma deal ahead of trilogue ...

So-called compulsory licensing is allowed under World Trade Organization (WTO) rules in emergencies as a waiver of normal regulations and could be applied during the COVID-19 pandemic.

Novartis chief criticises EU move to control pharma licensing in emergencies on whatsapp (opens in a new window) Save. Donato Paolo Mancini and Hannah Kuchler in London. April 25 2023.